Novel Pyrrolyl 2-aminopyridines As Potent and Selective Human Beta-secretase (BACE1) Inhibitors
Overview
Authors
Affiliations
The proteolytic enzyme beta-secretase (BACE1) plays a central role in the synthesis of the pathogenic beta-amyloid in Alzheimer's disease. Recently, we reported small molecule acylguanidines as potent BACE1 inhibitors. However, many of these acylguanidines have a high polar surface area (e.g. as measured by the topological polar surface area or TPSA), which is unfavorable for crossing the blood-brain barrier. Herein, we describe the identification of the 2-aminopyridine moiety as a bioisosteric replacement of the acylguanidine moiety, which resulted in inhibitors with lower TPSA values and superior brain penetration. X-ray crystallographic studies indicated that the 2-aminopyridine moiety interacts directly with the catalytic aspartic acids Asp32 and Asp228 via a hydrogen-bonding network.
Stockinger F, Poc P, Mohwald A, Karch S, Hafner S, Alzheimer C J Med Chem. 2024; 67(12):10152-10167.
PMID: 38842406 PMC: 11215771. DOI: 10.1021/acs.jmedchem.4c00339.
Novel Anti-Alzheimer's Therapeutic Molecules Targeting Amyloid Precursor Protein Processing.
Uddin M, Kabir M, Jeandet P, Mathew B, Ashraf G, Perveen A Oxid Med Cell Longev. 2020; 2020:7039138.
PMID: 32411333 PMC: 7206886. DOI: 10.1155/2020/7039138.
BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer's Disease.
Maia M, Sousa E Pharmaceuticals (Basel). 2019; 12(1).
PMID: 30893882 PMC: 6469197. DOI: 10.3390/ph12010041.
Tsitovich P, Cox J, Spernyak J, Morrow J Inorg Chem. 2016; 55(22):12001-12010.
PMID: 27934305 PMC: 5553446. DOI: 10.1021/acs.inorgchem.6b02159.
Current pharmacotherapy and putative disease-modifying therapy for Alzheimer's disease.
Kulshreshtha A, Piplani P Neurol Sci. 2016; 37(9):1403-35.
PMID: 27250365 DOI: 10.1007/s10072-016-2625-7.